LYSOGENE: Positive efficacy signal from biomarker data | CORPORATE | EUR11(+253%)
LYSOGENE - CORPORATE | EUR11(+253%)Positive efficacy signal from biomarker data
LYS-SAF302 seems to work in the brain
Favourable comparison with Abeona Therapeutics data.
Next important step is the lift of clinical hold by the FDA
LYS-GM101 the other asset to not forget
Since 1996, Bryan, Garnier & Co has been growing with an absolute conviction that the investment banking landscape would experience a major revolution: most of the large local generalist banking groups will disappear to the benefit of a handful of global powerhouses, and an emerging group of independent, highly specialised boutique investment banks.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.